$RDGL

Weeks Brad Allan purchased $5K of RDGL

Weeks Brad Allan (President) purchased 60,000 shares of VIVOS INC (RDGL) at $0.08 across 2 trades over 2026-07-09 to 2026-07-10.

Original reporting
SEC EDGAR · Weeks Brad Allan
Published Jul 10, 2026, 5:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 10, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RDGL
Bullish
medium confidence
Mentioned
$RDGL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDGLBullishLow
01

Why it matters

The newest fact is the specific open-market purchase size, price, and dates, which may slightly influence sentiment but does not change the company’s disclosed financial outlook.

02

Market read

Traders may treat this as a small bullish sentiment datapoint, but it is unlikely to be a standalone driver of price without additional news.

03

What to watch

The article does not disclose motives, whether other insiders are buying/selling, or any concurrent company catalysts; RDGL’s microcap liquidity can amplify noise from small trades.

Relevance 4/10Novelty 5/10Timing: Filed 2026-07-10, covering purchases on 2026-07-09 to 2026-07-10.

Background

This is an SEC Form 4 insider transaction disclosure for Vivos Inc (RDGL) by its President, Weeks Brad Allan.

Company-level read

Ticker impact

$RDGLBullishMedium confidence
Context

Form 4 shows President Weeks Brad Allan bought 60,000 shares of RDGL at $0.0800/share on 2026-07-09 to 2026-07-10, direct holdings.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and should fade without additional company news.

Evidence & confidence

The filing is primary-source and time-stamped, but it is a small transaction ($4,800 total) with no 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or compensation-related and may not reflect improved fundamentals, especially at very small dollar totals.

Key entities

  • RDGL

    Vivos Inc, the company whose insider transaction is disclosed.

  • Weeks Brad Allan

    President of Vivos Inc, reported as the reporting insider on the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).